B48.4 Penicillosis

Name of the Condition

• Penicillosis

Summary

Penicillosis is a fungal infection caused by Penicillium marneffei, primarily affecting immunocompromised individuals. The condition can involve multiple organ systems, with the lungs, skin, and reticuloendothelial system being common sites of infection. It is endemic in parts of Southeast Asia and may present with systemic or localized manifestations, requiring prompt diagnosis and treatment to prevent progression.

Causes

The infection is caused by Penicillium marneffei, a dimorphic fungus found in soil and bamboo. Transmission occurs through inhalation of fungal spores or direct inoculation of the skin. The fungus can disseminate hematogenously, leading to widespread infection in susceptible hosts. Environmental exposure to contaminated soil or organic matter is the primary route of acquisition.

Risk Factors

• Immunocompromised states, such as HIV/AIDS, organ transplantation, or chemotherapy.
• Residence or travel to endemic regions (e.g., Southeast Asia, southern China).
• Prolonged exposure to soil or bamboo in endemic areas.
• Advanced age or chronic conditions that weaken immune function.

Symptoms

• Fever, chills, and weight loss (systemic symptoms).
• Cough, dyspnea, or chest pain (respiratory involvement).
• Skin lesions, such as papules, pustules, or umbilicated nodules.
• Hepatosplenomegaly or lymphadenopathy (reticuloendothelial involvement).
• Gastrointestinal symptoms, including diarrhea or abdominal pain.

Diagnosis

Diagnosis is confirmed by identifying Penicillium marneffei in clinical specimens, such as blood cultures, bone marrow aspirates, or tissue biopsies. Microscopic examination may reveal yeast-like cells with central septation. Serological tests or molecular assays can support identification, especially in endemic regions. Imaging studies may help assess organ involvement.

Treatment Options

Treatment typically involves antifungal therapy, such as amphotericin B followed by itraconazole or voriconazole. Duration depends on disease severity and immune status. Supportive care, including management of organ dysfunction, is essential. Long-term suppressive therapy may be required for immunocompromised patients to prevent relapse.

Prognosis and Follow-Up

Prognosis is generally favorable with early treatment, but severe or untreated cases can be fatal. Follow-up includes monitoring for treatment response, recurrence, or complications. Immunocompromised patients require ongoing surveillance to detect relapse or new infections. Regular clinical and laboratory evaluations are recommended during and after therapy.

Complications

• Disseminated infection affecting multiple organs.
• Respiratory failure or sepsis in severe cases.
• Chronic skin lesions or scarring.
• Relapse in immunocompromised individuals.
• Secondary bacterial infections due to skin breakdown.

Lifestyle & Prevention

• Avoid exposure to soil or bamboo in endemic areas, especially if immunocompromised.
• Use protective measures, such as masks or gloves, when handling potentially contaminated materials.
• Maintain good hygiene and wound care to reduce infection risk.
• For high-risk individuals, consider prophylactic antifungal therapy in endemic regions.

When to Seek Professional Help

Seek medical attention if you experience persistent fever, respiratory symptoms, or unexplained skin lesions, especially after travel to endemic areas or if you have a weakened immune system. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

Document the specific site of infection (e.g., pulmonary, cutaneous, or disseminated) and any underlying immunocompromised status, as these details may impact coding and clinical management. Ensure the diagnosis is confirmed by laboratory or histopathological findings to support accurate code assignment. Note the patient's exposure history or travel to endemic regions, as this may provide context for the infection.